Cassava Sciences Intrinsic Value Calculation – Cassava Sciences Poised for Potential Profits from Upcoming Phase 3 Readout
November 21, 2023
☀️Trending News
Cassava Sciences ($NASDAQ:SAVA) is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases like Alzheimer’s. With the upcoming Phase 3 readout scheduled for next year, the company stands to gain considerable profits if successful. Cassava Sciences is publicly traded on the NASDAQ, giving investors a chance to capitalize on the potential success of their upcoming trials. If successful, this could provide a major source of revenue for the company, as it would be the first drug of its kind available to treat neurodegenerative diseases. This could potentially lead to a huge increase in stock price if the drug is approved by regulators.
In addition, Cassava Sciences has multiple collaborations with other companies and organizations, which may provide additional sources of revenue. As such, investors should keep a close watch on any developments in the coming year.
Market Price
Cassava Sciences Inc. (CASSAVA) is set to release the results of its upcoming Phase 3 clinical trials soon, and investors are expecting the company to potentially make a profit from the release. Analysts are expecting favorable results from the trials for CASSAVA as they believe that the company will be able to show positive clinical and regulatory progress with their therapy for Alzheimer’s disease and other neurodegenerative diseases. Investors are optimistic about the potential for profit that could come from a successful readout of the results. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Cassava Sciences. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -95.43 | 76.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Cassava Sciences. More…
| Operations | Investing | Financing |
| -81.03 | -0.04 | 48.76 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Cassava Sciences. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 172.53 | 17.41 | 3.68 |
Key Ratios Snapshot
Some of the financial key ratios for Cassava Sciences are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | 76.3% |
| FCF Margin | ROE | ROA |
| -16.9% | -38.9% | -37.7% |
Analysis – Cassava Sciences Intrinsic Value Calculation
At GoodWhale, we have conducted an analysis of the fundamentals of CASSAVA SCIENCES. Through our proprietary Valuation Line, we have determined that the intrinsic value of a single share of CASSAVA SCIENCES is around $23.3. Currently, the stock is being traded at $22.8, making it a fair price that is slightly undervalued by 2.1%. More…
Peers
The company’s lead drug candidate is an orally available small molecule, PTI-125, which is in Phase 2 clinical trials for the treatment of Alzheimer’s disease. Cassava Sciences Inc has a strategic collaboration agreement with Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson, for the development and commercialization of PTI-125. Cassava Sciences Inc’s main competitors are Anavex Life Sciences Corp, Biogen Inc, Eli Lilly and Co.
– Anavex Life Sciences Corp ($NASDAQ:AVXL)
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the discovery and development of novel therapeutic drugs for the treatment of central nervous system diseases and cancers. The company’s lead drug candidate, ANAVEX 2-73, is currently being evaluated in a Phase 2 clinical trial for the treatment of Alzheimer’s disease. Anavex’s other drug candidates include ANAVEX 3-71, which is in Phase 1 clinical trials for the treatment of epilepsy, and ANAVEX 1037, which is in preclinical development for the treatment of Parkinson’s disease.
Anavex Life Sciences has a market capitalization of $872.96 million and a negative return on equity of 19.0%. The company’s lead drug candidate, ANAVEX 2-73, is currently being evaluated in a Phase 2 clinical trial for the treatment of Alzheimer’s disease. Anavex’s other drug candidates include ANAVEX 3-71, which is in Phase 1 clinical trials for the treatment of epilepsy, and ANAVEX 1037, which is in preclinical development for the treatment of Parkinson’s disease.
– Biogen Inc ($NASDAQ:BIIB)
Biogen Inc is a multinational biopharmaceutical company based in the United States. The company focuses on the discovery, development, and commercialization of therapies for the treatment of neurological and neurodegenerative diseases. As of 2022, Biogen has a market capitalization of 38.38 billion dollars and a return on equity of 14.98%.
– Eli Lilly and Co ($NYSE:LLY)
Eli Lilly and Co is a pharmaceutical company with a market cap of 312.67B as of 2022. The company has a Return on Equity of 45.88%. Eli Lilly and Co manufactures and markets prescription pharmaceuticals and over-the-counter products. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Summary
Cassava Sciences is a biotechnology company focused on treating Alzheimer’s Disease and other neurological conditions. Although the company’s share price has declined since the beginning of March, analysts are still optimistic about its long-term prospects due to the potentially high efficacy of its lead drug.
Related Posts
Recent Posts
